Home | Multiple Myeloma Hub

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Types Therapeutics Congresses Trials Expert Opinions

EBMT 2020

Multiple Myeloma Types

Editorial theme | What you need to know about high-risk multiple myeloma

In this article, you will find reviews of the current clinical landscape of high-risk multiple myeloma that has already been covered on the hub and what topics we will focus on...

Aug 11, 2020

| MM

Differences in safety profiles of panobinostat, ixazomib, elotuzumab, and daratumumab in real-world settings versus randomized controlled clinical trials

Eric P. Borrelli and Conor G. McGladrigan published in Journal of Oncology Pharmacy Practice a...

Aug 10, 2020

Belantamab mafodotin has been approved by the FDA for the treatment of patients with RRMM

The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin, an anti-B cell maturation antigen (BCMA) monoclonal antibody–drug conjugate...

Aug 7, 2020

Positive topline results from phase III APOLLO study of daratumumab plus pomalidomide and dexamethasone in the treatment of patients with RRMM

On July 31, 2020, positive results from the phase III APOLLO study were reported for daratumumab plus...

Aug 5, 2020

María-Victoria Mateos

" The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice. "

Featured Expert Opinion

Practice-changing abstracts at ASCO and EHA 2020

Interview with Multiple Myeloma Hub Co-Chair Sagar Lonial, Winship Cancer Institute at Emory University, on practice-changing...

EHA 2020

Predicting early relapse in patients with multiple myeloma

At the 25th European Hematology Association (EHA) Annual Congress, three posters outlined the latest advancements achieved by GIMEMA, the...

Aug 4, 2020

| EHA 2020

Results from the TOURMALINE-MM4 trial: Ixazomib for maintenance

During this year’s European Hematology Association (EHA) Annual Congress and the American Society of Clinical Oncology (ASCO) Annual...

Jul 31, 2020

| EHA 2020

What is the clinical value of adding daratumumab to CyBorD in the treatment of light-chain amyloidosis? Results from phase III ANDROMEDA study

The primary results investigating the efficacy and safety...

Jul 29, 2020

| EHA 2020

Pomalidomide + Vd for RRMM: Latest updates on the OPTIMISMM trial

The latest subanalyses of the phase III OPTIMISMM trial that investigated the use of the triplet pomalidomide (P), bortezomib (V),...

Jul 27, 2020

| EHA 2020

ASCO 2020

Is VRd or RAd induction more efficacious for patients with NDMM undergoing risk-adapted auto-SCT?

During the ASCO Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Stefan Knop, We...

Jul 27, 2020

| ASCO 2020

EVOLVE Trial: Can innovative orva-cel technology be a new option for patients with relapsed/refractory MM?

Orvacabtagene autoleucel (orva-cel) is under investigation as a B-cell maturation antigen...

Jul 23, 2020

| ASCO 2020

Selinexor triplets for relapsed/refractory multiple myeloma—an alternative to IMiD-based therapy?

A summary of the latest advances of selinexor in triplet regimens for the treatment of RRMM, as...

Jul 17, 2020

| ASCO 2020

Can daratumumab overcome the negative prognostic impact of high-risk cytogenetics? (I)

Interview with Smith Giri, University of Alabama at Birmingham, Birmingham, US.

Jul 15, 2020

| ASCO 2020

Conjugated antibodies

Belantamab mafodotin has been approved by the FDA for the treatment of patients with RRMM

The U.S. Food and Drug Administration (FDA) has approved belantamab mafodotin, an anti-B cell maturation...

Aug 7, 2020

Belantamab mafodotin gets positive recommendations from both EMA and FDA to be approved for the treatment of RRMM

Both the EMA and FDA give positive recommendations for the approval of belantamab...

Jul 28, 2020

Hot topics in MM: quadruplets and anti-BCMA therapy

During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub was pleased to speak to Saad Usmani, Levine Cancer...

Jun 24, 2020

| EHA 2020

The DREAMMs at ASCO — updates on belantamab mafodotin added to MM backbone therapies

A summary of new data from the DREAMM studies using belamaf in combination with other agents presented during the...

Jun 19, 2020

| ASCO 2020

Most Viewed

Practice-changing abstracts at ASCO and EHA 2020

Hot topics in MM: quadruplets and anti-BCMA therapy

What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

What are the latest advances in CAR T therapy?

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Editorial theme | What you need to know about high-risk multiple myeloma

Aug 11, 2020

| MM

Aug 10, 2020

Aug 7, 2020

Aug 5, 2020

| MM

María-Victoria Mateos

EHA 2020

Aug 4, 2020

| EHA 2020

Jul 31, 2020

| EHA 2020

Jul 29, 2020

| EHA 2020

Jul 27, 2020

| EHA 2020

ASCO 2020

Jul 27, 2020

| ASCO 2020

Jul 23, 2020

| ASCO 2020

Jul 17, 2020

| ASCO 2020

Jul 15, 2020

| ASCO 2020

Most Read

Conjugated antibodies

Aug 7, 2020

Jul 28, 2020

Jun 24, 2020

| EHA 2020

Jun 19, 2020

| ASCO 2020

Most Viewed